During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, ...

The FDA evaluates glofitamab and daratumumab for lymphoma and myeloma treatments, highlighting trial demographics and ...

During a live event, Nelson J. Chao, MD, asked participants how they employ the currently approved treatments for chronic GVHD.

Ayal Aizer, MD, MHS, discusses the findings of a phase 3 study investigating the use of stereotactic radiation vs whole-brain radiation in patients with 5 to 20 brain metastases.

Nicole A. Cipriani, MD, offers guidance for community oncologists regarding the role of BRAF p.V600E testing in patients with papillary thyroid carcinoma.

Hardeep Phull, MD, shared how telemedicine has transformed access, improved patient experience, and redefined care delivery for patients with cancer.

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

Breelyn Wilky, MD, discusses what key molecular insights in GIST management community oncologists should prioritize today.

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...

Final analysis of the INTRIGUE trial shows ripretinib offers similar survival rates and better safety compared to sunitinib ...